Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adderall XR for Cognitive Impairment in MS
NCT02676739Phase 3Active, not recruiting
- Start
- May 2016
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of adderall xr in cognitive impairment. Started May 2016; status: active, not recruiting.
02
Drugs
adderall xr
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT02676739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676739.